Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New implant aims to ease chronic pain for years

NCT ID NCT07507422

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 2 times

Summary

This study is tracking 970 adults with chronic pain who receive an Inceptiv™ spinal cord stimulator, a device that sends mild electrical pulses to the spine to block pain signals. Researchers want to see if at least half of patients get significant pain relief and better quality of life over six months and beyond. The goal is to confirm the device works well in real-world use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Inceptiv™ spinal cord stimulator (implantable device)
What this could lead to
If successful, this could confirm that the Inceptiv™ device provides lasting pain relief and improves quality of life for people with chronic pain.
What could go wrong
This is an observational post-market study, not a controlled trial, so results may be influenced by other factors. The device also carries surgical risks like infection or lead movement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 970 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Jan 2034

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The intended study population is adults with chronic, intractable pain of the trunk and/or limbs indicated for a Medtronic Inceptiv™ implantable neurostimulation system. Study eligibility criteria must be met to participate in this study.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. 18 years of age or older 2. Patient must be SCS therapy naïve 3. A clinical decision was made for the patient to receive an Inceptiv™ SCS system (pending satisfactory results from a Medtronic SCS trial) limited to on-label leads based on the specific geography for an on-label indication prior to enrollment in the study. 4. Patient is on stable opioid dosage for 3 months prior to enrollment, if applicable 5. Pain intensity of ≥ 6 as measured using the NPRS (0-10) in the predominant area(s) of pain that SCS is intended to treat 6. Patient must have an on-label indication specific to geography. * NOTE: Patients may be enrolled if they have upper limb radicular limb pain, related or unrelated to spine surgery * NOTE: In the US, patients experiencing chronic back pain without a history of spine surgery and not eligible for spine surgery are on-label candidates for SCS if the pain is associated with degenerative disc disease, herniated disc, or radicular pain syndrome. Radicular pain syndrome (with or without prior spine surgery) is an approved indication for SCS implant. 7. Diagnosis of chronic back and/or limb pain for an on-label indication lasting at least six months. Exclusion Criteria: 1. Has any existing or is planning to have a new active implantable neuromodulation device or system during the 5 year follow up period (e.g., peripheral nerve stimulation, sacral neuromodulation, intrathecal drug delivery system, a second SCS system) 2. Has a complex pain pattern that involves both upper and lower limbs or back and upper limb 3. Has a planned major medical procedure within 6 months before enrollment or after implant that may interfere with study results or confound results as determined by the Investigator 4. Has a planned interventional procedure within 6 weeks (+/- 2 weeks) before enrollment or after implant that may interfere with study results or confound results as determined by the Investigator 5. Major untreated or unstable psychiatric comorbidity, such as suicidal ideations, personality disorders, schizophrenia etc., that could interfere with accurate pain reporting, study procedures, and/or confound evaluation of study, as determined by the Investigator 6. Subjects with PCS total score \>30 are not eligible unless ALL of the following are met: 1. Absence of uncontrolled major psychiatric disorder or active suicidality based on clinical evaluation. 2. Investigator documentation of adequate understanding of therapy, realistic expectations, and anticipated compliance with protocol follow-up 7. Major non-indicated, untreated or refractory progressive disease (e.g., neurodegenerative disease {not including Diabetic Peripheral Neuropathy}, heart failure, cancer, osteoarthritis, fibromyalgia, chronic fatigue syndrome), or injury (e.g., fall resulting in hip fracture) that could interfere with accurate pain reporting, study procedures, and/or confound evaluation of study as determined by the Investigator 8. Has inpatient or outpatient admissions for drug or alcohol dependency within past 12 months or current/ongoing substance abuse 9. Has a current prescription of ≥90 morphine milligram equivalents (MME) per day 10. Has predominant mechanical back pain arising from facet or sacroiliac joint pain as the main cause of chronic low-back pain if low-back pain is the predominant pain condition, as determined by the Investigator 11. Has mechanical spine instability (eg. Spondylolisthesis grade 2) as determined by the Investigator 12. Has an active systemic or local infection that would delay trial or implant 13. Is pregnant or planning on becoming pregnant 14. Has a life expectancy of less than 1 year 15. Involved in an injury claim, under current litigation, beneficiary of an injury claim, receiving worker's compensation, or planning any future litigation 16. Has a condition that the Investigator determines would significantly increase perioperative risk (e.g., unstable or severe cardiac disease, liver disease, uncontrolled diabetes, kidney disease) Patients enrolled into the study with Diabetic Peripheral Neuropathy, Complex Regional Pain Syndrome and Upper Limb pain are required to meet further inclusion/exclusion criteria in order to contribute to the analysis for that particular condition. These criteria are designed to ensure that the patient's condition aligns with the standard diagnostic criteria set by applicable clinical guidelines. Painful Diabetic Peripheral Neuropathy (DPN) Inclusion Criteria * Clinical diagnosis of diabetes mellitus according to the American Diabetes Association guidelines (ADA). * Predominant pain condition being treated by SCS is lower-limb pain due to DPN * Hemoglobin A1c (HbA1c) must be \<8% within 6 months of enrollment for inclusion or have completed a preoperative risk assessment if \>8% * Presence of either numbness or at least one sensory disturbance (e.g., increased or decreased sensitivity, burning, pricking/stabbing, aching, "pins and needle" sensation) in the foot/feet. Painful DPN Exclusion Criteria * Lower-limb pain not associated with DPN or that cannot be distinguished from DPN (e.g., mononeuropathies, proximal neuropathies, nonneuropathic pain, peripheral vascular disease) * History of lower-limb amputation or planned lower-limb amputations due to diabetes * Large (≥3cm) and/or gangrenous ulcers or active infection of the lower limbs Complex Regional Pain Syndrome (CRPS) Inclusion Criteria * Meets diagnostic criteria for CRPS (International Association for the Study of Pain "Budapest Criteria") * Disease that is clinically restricted to one hand or foot and affects the entire hand, foot or lower extremity * CRPS is the predominant pain condition that SCS is intended to treat CRPS Exclusion Criteria * Presence of Reynaud's disease * Current or previous neurologic abnormalities unrelated to CRPS * Another condition affecting the function of the diseased or contralateral extremity * Dystonia as a predominant component of their presentation Upper Limb Pain (ULP) - non CRPS Inclusion Criteria * Be diagnosed with radicular pain syndrome, or be diagnosed with radicular pain secondary to failed back surgery or herniated disk ULP - non CRPS Exclusion Criteria * Has significant cervical stenosis, as determined by the Investigator * Failed treatments of carpal tunnel syndrome and/or cubital tunnel syndrome * Has mechanical neck pain (e.g., facet spondylosis), as determined by the Investigator * Any previous history of surgery on the posterior elements (laminectomy, posterior fusion) of the cervical spine * Has brachial plexus injury as predominant cause of pain

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Chronic Pain chronic pain syndrome Pain, Intractable

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Center for Pain and Supportive Care

    RECRUITING

    Phoenix, Arizona, 85028, United States

  • Christian Hospital

    RECRUITING

    St Louis, Missouri, 63136-6119, United States

  • Christus Surgery Center- Westover Hills, LLC

    RECRUITING

    San Antonio, Texas, 78251, United States

  • Hôpital Claude Huriez

    RECRUITING

    Lille, Cedex, 59037, France

  • North Texas Orthopedics and Spine Center

    RECRUITING

    Houston, Texas, 76051-3930, United States

  • Relieve Pain Center

    RECRUITING

    San Diego, California, 92110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.